Detalles de la búsqueda
1.
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
N Engl J Med
; 390(8): 723-735, 2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38381675
2.
Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone.
J Clin Psychopharmacol
; 30(1): 25-33, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20075644
3.
Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
Clin Neuropharmacol
; 42(1): 4-8, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30520758
4.
Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations.
Parkinsons Dis
; 2018: 9763057, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30425824
5.
Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease.
Neuropsychiatr Dis Treat
; 14: 839-845, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29606877
6.
Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
Clin Neuropharmacol
; 41(2): 47-55, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29432286
7.
Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Clin Ther
; 29(5): 874-888, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17697906
8.
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
J Neurol Sci
; 373: 116-123, 2017 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28131167
9.
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
CNS Drugs
; 29(4): 341-50, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25895021
10.
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
J Parkinsons Dis
; 5(4): 837-45, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26444090
11.
Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial.
JAMA
; 291(11): 1333-41, 2004 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-15026400
12.
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Parkinsonism Relat Disord
; 20(12): 1335-40, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25306200
13.
Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.
J Opioid Manag
; 5(2): 97-105, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19507806
14.
Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
Curr Med Res Opin
; 23(5): 981-9, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17519065
Resultados
1 -
14
de 14
1
Próxima >
>>